Sunesis Pharmaceuticals — Merger or Acquisition (November 2020)
11 slides from Sunesis Pharmaceuticals's merger presentation, Nov 30, 2020
Slide 1: Precision Oncology Company Targeting Virus-Associated Cancers
Precision Oncology Company Targeting Virus-Associated Cancers November 30, 2020 Exhibit 99.2
Slide 2: Forward-Looking Statements
This communication contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: expected timing, completion and effects of the proposed merger of Sunesis Pharmaceutics, Inc, (“Sunesis”) and Vira
Slide 3: Additional Information on the Proposed Transaction
Additional Information on the Proposed Transaction Additional Information and Where to Find It Sunesis plans to file with the SEC, and the parties plan to furnish to the security holders of Viracta and Sunesis, a Registration Statement on Form S-4, which will constitute a prospectus of Sunesis and w
Slide 4: Viracta Therapeutics – Sunesis Pharmaceuticals Merger
Viracta Therapeutics – Sunesis Pharmaceuticals Merger Viracta Therapeutics and Sunesis Pharmaceuticals agree to merge in an all-stock transaction and the combined company is expected to trade on Nasdaq under new symbol VIRX Viracta shareholders are expected to own approximately 86% of the combined c
Slide 5: Viracta: Unique Convergence of Disciplines to Treat Virus-Associated Malignancies
Viracta: Unique Convergence of Disciplines in Company to Treat Virus-Associated Malignancies Oncology Virology Immunology Epigenetics Viracta recently completed a $40 million Series E Preferred Stock equity financing, led by aMoon Concurrent with the execution of the merger agreement, Viracta entere
Slide 6: Leadership Team
Leadership Team Ivor Royston, MD President and Chief Executive Officer Hybritech Douglas Faller, MD, PhD Chief Scientific Officer Xiaohu Deng, PhD Senior VP, Product Development Lisa Rojkjaer, MD Chief Medical Officer Robert McRae VP, Operations & Strategic Alliances Daniel Chevallard, CPA Chief Fin
Slide 7: Introduction to Viral Infections and Cancer
Introduction to Viral Infections and Cancer 15-20% of Cancers Worldwide Contain Viral Genomes Viral Genomes Oncogenic Proteins Viral Infection & Cancer HPV HCV Liver cancer Cervical, oropharyngeal cancer E6, E7 Core, N53, NS5A MCV Merkel cell carcinoma LT, sT KSHV Kaposi’s sarcoma, etc. LANA, viRF,
Slide 8: EBV Biomarker: Detection and Prognostic Significance
EBV Biomarker: Detection and Prognostic Significance Dark blue: EBV genome DLBCL Plasmablastic NK/T Source: Lu TX, et al. Sci Rep 5,12168, 2015; Haverkos BM et al. Int J Cancer. 2017, Park et al, Blood, 2007. Ding et al, Int J Clin Exp Med, 2016. . Peripheral T cell lymphoma (PTCL) DLBCL EBV positiv
Slide 9: Viracta's Synthetic Lethality Approach Selectively Targets EBV+ Cancer Cells
Viracta’s Synthetic Lethality Approach Selectively Targets EBV+ Cancer Cells Latency EBV is latent in cancer cells and viral kinase genes are silenced epigenetically. Valganciclovir (VGCV), an antiviral prodrug of GCV, is inactive in the absence of the expression of viral protein kinase kinase Laten
Slide 10: Pipeline: Innovative Approaches to Virus-associated Cancers
Program Preclinical Phase 1 Phase 2 Registration Trial Nstat/VGCV for EBV+ Lymphoma Expected 1H2021 Nstat/VGCV for EBV+ Solid Tumors Expected 2021 Other Virus-associated Malignancies Orphan Drug Designations granted for nanatinostat in combination with valganciclovir for treatment of: T cell lymphom
Slide 11: Viracta: Well-positioned to advance its novel oral therapy for EBV+ tumors
Viracta: Well-positioned to advance its novel oral therapy for EBV+ tumors EBV+ cancers: Orphan diseases with high unmet medical need, poor prognosis and no approved therapies Viracta’s approach: Novel biomarker-directed therapy with oral delivery - targets EBV+ tumor cells by “Synthetic Lethality”
Sunesis Pharmaceuticals — Merger or Acquisition (November 2020) on 6ix